5635-67-6

Usage

Uses

Used in Pharmaceutical Industry:
(3,4-Dichlorobenzyl)methylamine is used as a reagent in the synthesis of various pharmaceuticals, including antihistamines and local anesthetics, for its ability to contribute to the development of effective medications that address allergic reactions and provide pain relief.
Used in Agricultural Chemicals:
In the agricultural sector, (3,4-Dichlorobenzyl)methylamine is utilized as an intermediate in the production of pesticides and other agricultural chemicals, playing a crucial role in creating compounds that protect crops and enhance agricultural productivity.
Used in Organic Synthesis:
As a versatile chemical compound, (3,4-Dichlorobenzyl)methylamine is employed as a reagent in organic synthesis for the creation of a wide range of chemical products, showcasing its adaptability in chemical reactions and product development.
Used in Neurological Disorders Research:
(3,4-Dichlorobenzyl)methylamine has been studied for its potential use in the treatment of neurological disorders, indicating its possible role in developing therapeutic agents that could alleviate symptoms or treat the underlying causes of such conditions.
Used in Drug Compound Development:
Furthermore, (3,4-Dichlorobenzyl)methylamine serves as a building block in the creation of novel drug compounds, highlighting its importance in the advancement of pharmaceutical research and the discovery of new medications.

InChI:InChI=1/C8H9Cl2N/c1-11-5-6-2-3-7(9)8(10)4-6/h2-4,11H,5H2,1H3/p+1

Upstream product

• 6077-76-5 3,4-dichloro-N-methylbenzamide 
• 593-51-1 methylamine hydrochloride 
• 6287-38-3 3,4-dichlorobenzaldehyde 
• 74-89-5 methylamine 
• 874-42-0 2,4-dichlorobenzaldeyhde 
• 17947-66-9 (3,4-dichloro-benzylidene)-methyl-amine 

Downstream Products

• 55245-69-7 C₉H₈Cl₃NO 
• 76532-16-6 N⁶-<(3,4-dichlorophenyl)methyl>-N⁶-methyl-2,4,6-pteridinetriamine 
• 93683-75-1 6-[(3,4-Dichloro-benzyl)-methyl-amino]-3-nitro-pyridine-2-carbonitrile 
• 74655-01-9 4-(2-Cyano-phenyl)-2-diethoxymethyl-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 5-{2-[(3,4-dichloro-benzyl)-methyl-amino]-ethyl} ester 3-ethyl ester 
• 74655-35-9 2-Diethoxymethyl-6-methyl-4-(2-trifluoromethyl-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid 5-{2-[(3,4-dichloro-benzyl)-methyl-amino]-ethyl} ester 3-ethyl ester 
• 92144-31-5 2,4-Diamino-quinazoline-6-sulfonic acid (3,4-dichloro-benzyl)-methyl-amide 
• 74654-94-7 2-Diethoxymethyl-6-methyl-4-(3-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid 5-{2-[(3,4-dichloro-benzyl)-methyl-amino]-ethyl} ester 3-ethyl ester 
• 112780-94-6 3-[(3,4-Dichloro-benzyl)-methyl-amino]-1-phenyl-propan-1-one 
• 93683-88-6 3-Amino-6-[(3,4-dichloro-benzyl)-methyl-amino]-pyridine-2-carbonitrile 
• 93684-00-5 2,4-diamino-6-<(3,4-dichlorobenzyl)methylamino>pyrido<3,2-d>pyrimidine 
• 931418-46-1 N-(3,4-dichlorobenzyl)-N-(methyl)ethane-1,2-diamine 
• 1092060-50-8 C₂₅H₂₃Cl₂FN₂ 
• 1092060-62-2 C₂₆H₂₅Cl₂FN₂ 
• 1191244-95-7 5-(3,5-dichloro-4-hydroxyphenyl)-N-(3,4-dichlorobenzyl)-N-methyl-1H-1,2,4-triazole-3-carboxamide 

Relevant academic research and scientific papers

Novel non-ATP competitive small molecules targeting the CK2 α/β interface

Increased CK2 levels are prevalent in many cancers. Combined with the critical role CK2 plays in many cell-signaling pathways, this makes it a prime target for down regulation to fight tumour growth. Herein, we report a fragment-based approach to inhibiting the interaction between CK2α and CK2β at the α-β interface of the holoenzyme. A fragment, CAM187, with an IC50 of 44 μM and a molecular weight of only 257 gmol?1 has been identified as the most promising compound. Importantly, the lead fragment only bound at the interface and was not observed in the ATP binding site of the protein when co-crystallised with CK2α. The fragment-like molecules discovered in this study represent unique scaffolds to CK2 inhibition and leave room for further optimisation.

Oxidations with Cerium(IV) Sulfate: Intramolecular Cyclization of N-Benzyl-&β-aminoketones Yielding 4-Benzoyl-1,2,3,4-tetrahydroisoquinolines

Preparation and regiospecific cerium(IV) sulfate of the substituted N-benzyl-β-aminoketones 3 are described. 4-Benzoyl-1,2,3,4-tetrahydroisoquinolines 4 so obtained are reduced by sodium borohydride.

Benzylamines: Synthesis and evaluation of antimycobacterial properties

The synthesis of benzylamines with various N-alkyl chains and substituents in the aromatic system as well as their evaluation on Mycobacterium tuberculosis H 37 Ra are described. The most active compounds in this test, N-methyl-3-chlorobenzylamine (MIC 10.2 μg/mL), N-methyl-3,5-dichlorobenzylamine (93, MIC 10.2 μg/mL), and N-butyl-3,5-difluorobenzylamine (MIC 6.4 μg/mL), also exhibited a marked inhibitory effect on Mycobacterium marinum and Mycobacterium lufu used for the determination of antileprotic properties. The combination of 93 with aminosalicylic acid, streptomycin, or dapsone exert marked supra-additive effects on M. tuberculosis H 37 Ra.

Folate Antagonists. 18. Synthesis and Antimalarial Effects of N6-(Arylmethyl)-N6-methyl-2,4,6-pteridinetriamines and Related N6,N6-Disubstituted 2,4,6-Pteridinetriamines

N6-(Arylmethyl)-N6-methyl-2,4,6-pteridinetriamines (1-5) and related N6-substituted 2,4,6-pteridinetriamines (16-20) were obtained by the condensation of 6-chloro-2,4-pteridinediamine with methylarylmethanamine and other selected secondary amines.The requisite N-methylarylmethanamines (21-32) were prepared by the hydrogenation over Pt/C of the corresponding arylcarboxaldehyde in the presence of methanamine.Several of the N6-(arylmethyl)-N6-methyl-2,4,6-pteridinetriamines exhibited exceptional suppressive antimalarial activity against a drug-sensitive line of Plasmodium berghei in mice.N6-Methyl-N6-(1-naphthalenylmethyl)-2,4,6-pteridinetriamine (9), the most active of those compounds, was also shown to be curative at 3.16 mg/kg in a single oral dose against P. cynomolgi in the rhesus monkey.This compound was also shown to be effective against a chloroquine-resistant line of P. berghei in the mouse but showed cross-resistance to a pyrimethamine-resistant strain.Most of the 2,4,6-pteridinetriamines showed strong antibacterial action against Streptococcus faecalis and Staphylococcus aureus.